The interplay between adipokines and body composition in obesity and metabolic diseases
Wegovy acts on the GLP-1 receptor to help control appetite, while Mounjaro targets both the GLP-1 and GIP receptors, which may enhance its effect in some patients
Sustained weight loss significantly reduces apnea severity
If approved, Wegovy will be the first GLP-1 agent to treat MASH
However, their use should always be guided by professional advice, realistic expectations, and an informed understanding of the benefits and limitations
As a rule of thumb, they require verification of a diagnosis of type 2 diabetes, along with specific laboratory or clinical criteria, such as high hemoglobin A1C levels or fasting plasma glucose levels